Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 1996

View Archived Issues

BTG-2403: representative opioid analgesic

Glaxo Wellcome's Ultiva receives FDA approval

5-HT1-like receptor agonists as migraine treatment from Merck & Co.

Taro's clobetasol propionate approved by FDA

Stiefel to develop and market CytoMed's CMI-392

Vanguard Medica exercises worldwide rights to VML-262

Penederm files FDA amendment regarding Avita

FDA approval granted for Candela's ALEXlazr

Antibacterial cephalosporins described by Lilly

Antibacterial naphthyridines in Cheil Foods & Chemicals' pipeline

BE-43767A: Banyu's most active novel antibacterial from new series

Benzyl pyrimidine antibacterial agents from Roche

Antibacterial benzimidazole derivatives from Roche

Saricandin: Abbott's novel papulacandin antifungal antibiotic

Cantab's DISC HSV-2 cleared in U.K. for testing in genital herpes

Pharmacia & Upjohn seeks FDA approval for Rescriptor

Protease inhibitor plus Epivir/Retrovir cocktail shows positive anti-HIV results

Triple anti-HIV therapy shows positive results

Zadaxin/zidovudine/interferon alpha combination enhances immune system

Theratechnologies' AIDS gene therapy shows promising results

Hybridon's GEM-91 inhibits various steps in HIV-1 replication

Cel-Sci's HGP-30 vaccine associated with IgG3 isotype antibody response

CryptoGam enters phase II for cryptosporidiosis in AIDS patients

Interim results from ALRT-1057 phase I/II trials

Positive phase I/II results for PDT's SnET2 in AIDS-associated Kaposi's sarcoma patients

Matrix metalloproteinase inhibitors from Roche Bioscience and Agouron

Antiinflammatory peptides for rheumatiod arthritis treatment from Italfarmaco

Dexketoprofen salts with analgesic and antiinflammatory action described by Menarini

Roche describes compounds useful for treating arthritis

SC-58125: Another selective COX-2 inhibitor from Searle

Immunosuppressants reported by DuPont Merck

American Home Products issued U.S. patent for 42-epi-rapamycin

Teijin reports naphthalene derivatives with immunosuppresive activity

SangStat initiates bioequivalence trials of its ciclosporin formulation

1996 ragweed season trial of Allervax initiated

SmithKline Beecham's DTaP vaccine receives unanimous advisory committee approval

Antitumor platinum complexes disclosed by Boehringer Mannheim

ACIC research reveals antineoplastic agents

SS-288A/SS-288B: mew anthracycline antibiotics from Mercian

More anthracycline antibiotics from Mercian

Alfacell's Onconase warrants combination therapy studies

Potent selective protein farnesyltransferase inhibitor from Pierre Fabre

Clarion's CPR-1007 shows antitumor, antipsoriatic and antiinflammatory activity

Cell-cell adhesion-regulating proteins as antitumor treatment

Suppressin from pituitary extract described by the University of Alabama

O6-alkylguanine-DNA alkyltransferase inactivators disclosed

Pharmos receives grant to develop loteprednol/tobramycin combination product

Cathepsin L inhibitors described by Takeda

Vitamin D compounds with preferencial calcemic and cell differation inducing activity described

Bile acid reabsorption inhibitors described by Glaxo Wellcome

Cholesterol absorption inhibitors from Schering-Plough

ImmuCell and Agri-Mark form joint venture for bovine lactoferrin production and commercialization

KGF in preclinical development in Japan for mucositis

Hemosol's hemoglobin manufacturing process covered under U.S. patent

Data on withdrawal from benzodiazepine treatment

FDA has cleared FlexSure, a whole-blood diagnostic

Biopool International's TintElize approved by FDA

Avitar Technologies and Genua sign collaborative agreement

Bard BTA TRAK update

BioSource International begins feasibility study of breast cancer detection technique

Matritech receives FDA approval for NMP22 Test Kit

Ostagen: NovaDx's osteoporosis diagnostic

Promising phase III results for Molecular Biosystem's FS069

Neoprobe's RIGScan CR49 undergoes European review

Positive phase I/II trial results for Parkinson's diagnostic, Altropane

Positive trial results of Janssen's sabeluzole in obstructive sleep apnea patients

5-HT1A receptor-selective agents from American Home Products

Neurogen reveals D3/D4 receptor-selective compounds

Abbott's Serlect receives FDA marketing approval

Genome Therapeutics and Merck & Co. sign licensing agreement

C-Maf T-cell switch factor: Important component of Boston Life Science's R&D

Roche begins screening for obesity drug candidates

Neuropeptide Y Y5 receptor linked to obesity and eating disorders

Stat4 gene research at Tularik and Harvard University

Myriad Genetics and Intermountain Health Care collaborate on CNS disorders

Search for new drug using genomic technology brings together 3 companies in collaboration

CytoTherapeutics announces new biotech company

University of Michigan issued U.S. patent for gene transfer technology

Binary Therapeutics and Xytronyx shareholders approve merger agreement

Cytokine Sciences acquires Innovative Therapeutics

European Commission approves Sandoz/Ciba-Geigy merger

Ethical Holdings acquires Beta Pharmaceuticals

Athena Neurosciences acquires worldwide rights to new formulation of Carbatrol

GDNF vital for kidney and enteric nervous system development

Athena Neuroscience's BotB successfully completes phase II in cervical dystonia

Muscarinic cholinergic ligands described by Novo Nordisk

Adenosine A1 antagonists described by German universities

Trial results described for methylphenidate in head injury patients

5-Lipoxygenase inhibitors reported by Pfizer

Kyoto Pharm. and Asahi Chem. to codevelop AKY-953

Anti-IgE monoclonal antibody lawsuits settled

Angiotensin II antagonists described by Kotobuki Seiyaku

NEP inhibitors described by Tanabe Seiyaku

Potential hypertension treatment from Pola

PST-2238: a selective Na+/K+-ATPase inhibitor

Imidapril available in Pakistan and Korea

Benzofuran smooth muscle proliferation inhibitors from Lilly

LDL oxidation inhibitors as arteriosclerosis/myocardial ischemia treatment from Chugai

FO-2047: Kitasato Institute's lipid peroxidation inhibitor

Lynx Therapeutics' LR-3280 licensed to Tanabe Seiyaku

Alexion awarded U.S. patent for monoclonal antibodies

Serine elastase inhibitor: A promising cardiovascular therapeutic

RB-106: INSERM's NEP/ACE inhibitor

Hoechst Marion Roussel synthesizes TNF-alpha production inhibitor

BASF reveals thrombin inhibitor as thrombosis/arterial reocclusion therapy

Fibrinogen antagonists from Merck & Co.

Fibrinogen antagonists from DuPont Merck

Platelet aggregation inhibitors from Meiji Seika

Terumo discloses fibrinogen (gpIIb/IIIa) antagonists

C85: TxB2 production/phosphoinositide breakdown inhibitor

AlphaNine SD cleared by FDA

The Immune Response Corporation and Bayer to codevelop hemophilia A gene therapy

Glaxo Wellcome describes alpha1A-adrenoceptor antagonists

CGP-53153: Ciba-Geigy's steroidal 5alpha-reductase inhibitor as BPH therapy

Positive results in trial of Cystistat in refractory interstitial cystitis patients

CJ-12954: Pfizer's anti-Helicobacter pylori compound

Janssen describes agent for decreased intestinal motility

SmithKline Beecham's new Havrix formulation receives Canadian approval

Alferon N injection undergoes phase III in HCV

Pharmacia & Upjohn reveals non-enzymatic protein glycosylation inhibitors

Neocrin obtains exclusive rights to University of Texas patent

Harvard Scientific's liposomal prostaglandin E1 begins clinical trials

RPR receives marketing approval for Menorest in four countries

Organon's Puregon more effective than traditional fertility hormone

High continuation rate demonstrated for Norplant in first year of use

Lea's Shield demonstrates contraceptive efficacy and safety

Ono's Ono-4057 shows immunosuppressive effects in preclinical trials

Didronel receives 22nd marketing approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...